Successfully commenced U.S. commercial launch of LUMRYZ™ Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 Significant early progress on payor coverage, prescriber certifications and patient enrollments Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform
DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of the American Academy of Sleep Medicine (AASM) Foundation’s 15th Annual Young Investigators Research Forum (YIRF). This will be Avadel’s third year as lead sponsor of the YIRF program, which takes place March-June 2023, with virtual events and in-person events. Avadel has supported AASM Foundation’s YIRF